

EXHIBIT I


Sunomix website as of September 2020 (Technology)

Improving human health everywhere. Science without fear

f •• •• ••

Sunomix Therapeutics

Home About Us Technology Platforms Pipeline Partnerships Careers Contact Us



3D Model of COVID-19 SAPN

Diagram illustrating the 3D Model of COVID-19 SAPN. It shows the process from Protein Monomers to Refolding to Refolded SAPN. The Refolded SAPN is shown as a complex, multi-colored, star-shaped nanoparticle structure.

Technology

We have a vaccine platform (self-assembling protein nanoparticles – SAPNs) that can – and now has been – rapidly adopted to COVID-19. SAPNs have been demonstrated for many different disease models like influenza, malaria, toxoplasmosis, etc. to induce a robust and protective immune response. Most importantly, ten years ago our SARS vaccine has induced 70% neutralization in an *in vitro* assay. As protein drugs, SAPNs can easily and rapidly be produced by standard biotechnology procedures. And finally, the malaria-SAPN is currently being evaluated in phase I/IIa clinical trial.

How it works

Protein chains are designed to be able to self-assemble into highly immunogenic protein nanoparticles. Those protein chains display the SARS-2 related epitopes while at the same time immuno-stimulatory molecules are incorporated into the nanoparticle to render the SAPN highly immunogenic.

Our highly immunogenic and non-infectious nanoparticles offer unmet flexibility for immunogen design. 50 copies of epitopes or proteins assemble into nanoparticles just like VLPs and are able to display protein epitopes in their native conformation. Since the nanoparticles are very easy to produce, many different designs can be tested rapidly.

Our HSV-ST1948 vaccine prototype induces a very strong immune response due to the repetitive display of antigens, they promote strong CD4 and CD8 T cell immune responses by incorporating the T cell epitopes into the core architecture of the nanoparticle; and they trigger a strong innate immune response by activating the TLR5 and TLR9 pathways through built-in adjuvants. As a result, we induce an immune response that is orders of magnitude stronger than KLH, a standard vaccine carrier in modern immunology. SAPN Technology has been used to design vaccines for various infectious diseases (Herpes, HIV, SARS, Malaria, and influenza).